A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway Translational Blockade of Immune Checkpoints

By Li Yongshu   Li Fangfei   Jiang Feng   Lv Xiaoqing   Zhang Rongjiang   Lu Aiping   Zhang Ge  

International Journal of Molecular Sciences, Vol. 17, Iss. 7, 2016-07 ,pp. : 1151-1151

MDPI

Access to resources Recommend Favorite

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

By Abdin Shifaa M.   Zaher Dana M.   Arafa El-Shaimaa A.   Omar Hany A.  

Cancers, Vol. 10, Iss. 2, 2018-01 ,pp. : 32-32

MDPI

Access to resources Recommend Favorite

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients

By Botti Gerardo   Collina Francesca   Scognamiglio Giosuè   Rao Federica   Peluso Valentina   De Cecio Rossella   Piezzo Michela   Landi Gabriella   De Laurentiis Michelino   Cantile Monica   Di Bonito Maurizio  

International Journal of Molecular Sciences, Vol. 18, Iss. 2, 2017-02 ,pp. : 459-459

MDPI

Access to resources Recommend Favorite

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types

By Scognamiglio Giosuè   De Chiara Anna   Di Bonito Maurizio   Tatangelo Fabiana   Losito Nunzia Simona   Anniciello Annamaria   De Cecio Rossella   D’Alterio Crescenzo   Scala Stefania   Cantile Monica   Botti Gerardo  

International Journal of Molecular Sciences, Vol. 17, Iss. 5, 2016-05 ,pp. : 790-790

MDPI

Access to resources Recommend Favorite

Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis

By Cho Hyosun   Kang Hyojeung   Lee Hwan Hee   Kim Chang Wook  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1517-1517

MDPI

Access to resources Recommend Favorite